// App-Quantinova.ai

SAT0152 : EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS WITH 3 YEARS OF TREATMENT: RESULTS FROM A LONG-TERM STUDY

Researchers

Presenter

  • J. S. Smolen

Principal Investigators

  • L. Xie

  • B. Jia

  • P. C. Taylor

  • G. R. Burmester

  • Y. Tanaka

  • A. Elias

  • A. Cardoso

  • R. Ortmann

  • C. Walls

  • M. Dougados

Medical Centers

  • Medical University of Vienna, Division of Cardiology, Vienna, Austria

  • Eli Lilly and Company, Indianapolis, United States of America

  • University of Oxford, Oxford, United Kingdom

  • Charite-University Medicine Berlin, Berlin, Germany

  • University of Occupational and Environmental Health, Kitakyushu, Japan

  • Hopital Cochin, Paris, France

Locations

  • Austria

  • United States

  • United Kingdom

  • Germany

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Baricitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved